[192 Pages Report] The global creatinine assay kits market is valued at USD 182.7 Million in 2016 and is projected to reach USD 245.4 Million by 2022, at a CAGR of 5.3%. The base year considered for the study is 2016 and the forecast period is from 2017 to 2022.

The objectives of this study are as follows:

To define, describe, and forecast the global creatinine assay kits on the basis of type, type of sample, and region

To estimate the total number of Creatinine Measurement tests conducted by type and region

To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, and industry-specific challenges)

To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall market

To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for the market leaders

To forecast the size of the market with respect to five regions: North America, Europe, Asia, and the Rest of the World (RoW)

To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies

To track and analyze competitive developments in the creatinine assay kits industry, such as acquisitions, agreements, product launches & upgrades, expansions, and R&D activities

Research Methodology

The study estimates the market size for 2017 and projects its demand till 2022. In the primary research process, various sources from both demand side and supply side were interviewed to obtain qualitative and quantitative information for the report. Primary sources from the demand side include physicians/doctors, healthcare professionals, clinical laboratory executives, lab managers, laboratory assistants, and biochemistry consultants.

For the market estimation process, both top-down and bottom-up approaches were used to estimate and validate the market size of the creatinine assay kits market as well as to estimate the market size of various other dependent submarkets. All possible parameters that affect the market covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. This data was consolidated and added to detailed inputs and analysis from MarketsandMarkets and presented in this report. Secondary sources such as directories; databases such as D&B, Bloomberg Business, and Factiva; white papers; annual reports; company house documents; investor presentations; and SEC filings of companies were referred.

To know about the assumptions considered for the study, download the pdf brochure

The market is highly fragmented with the presence of several small and big players. Prominent players in this market include Thermo Fisher Scientific (US), Merck (Germany), Abbott Laboratories (US), Abcam (UK), Quidel (US), Enzo Life Sciences (US), Cayman Chemical (US), Cell Biolabs (US), Genway Biotech (US), BioAssay Systems (US), Wako Pure Chemical Industries (Japan), Tulip Diagnostics (India), BioVision (US), and Arbor Assays (US).

Target Audience for this Report:

Creatinine assay kit manufacturers

Creatinine assay kit distributors

Hospitals

Research and consulting firms

Venture capitalists

Regulatory bodies

Academic centers

Teaching hospitals and academic medical centers (AMCs)

Contract manufacturing organizations (CMOs)

Contract research organizations (CROs)

Scope of the Report

This report categorizes the market into following segments and subsegments:

Creatinine Assay Kits Market, by Type

Jaffe�s Kinetic Test Kits

Creatinine-PAP Test Kits

ELISA Test Kits

Creatinine Assay Kits Market, by Type of Sample

Blood/Serum

Urine

Other Samples

Creatinine Assay Kits Market, by Region

North America US Canada

Europe Germany UK France RoE

Asia Japan China India Indonesia RoA

Rest of the World (RoW) Brazil Other RoW Countries



Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company�s specific needs.

The following customization options are available for this report.

Company Information

Detailed analysis and profiling of additional market players (up to 5)

The global creatinine assay kits market is expected to reach USD 245.4 Million by 2022 from USD 189.6 Million in 2017, at a CAGR of 5.3%. The growth of this market is mainly driven by the increasing incidence of renal disorders, growing incidence of other chronic disorders impacting renal function, growing awareness and adoption of preventive healthcare, favourable government initiatives to promote renal health, rapid growth in the geriatric population, and advancements in biomedical research pertaining to kidney disorders and availability of funding.

This report segments the market on the basis of type, type of sample, and region. By type, the market is segmented into Jaffe�s kinetic test kits, Creatinine-PAP test kits, and ELISA test kits. In 2017, the Jaffe�s kinetic test kits segment accounted for the largest share of the market, since it is the oldest and most conventional method for creatinine measurement. Additionally, wide product availability and cost-effectiveness of these kits are some of the other major factors responsible for the large share of this segment.

Based on type of sample, the market is segmented into blood/serum, urine, and other samples. The urine samples segment accounted for the largest share of the market in 2017, owing to ease of sample availability and non-invasive method of sample collection. The blood/serum segment is expected to witness the fastest growth over the forecast period, as it ensures greater result accuracy.

In 2017, North America dominated the market followed by Europe. Asia is expected to grow at the highest CAGR during the forecast period. This can be attributed to factors such as the large population base in Asian countries, growing geriatric population, growing prevalence of CKD, rising awareness towards preventive healthcare, improving healthcare infrastructure, and growing focus of market players on addressing demands in these countries. The increasing prevalence of infectious diseases and metabolic syndromes in this region is resulting in the high and regular prescription for metabolic tests.

On the other hand, limited usage of creatinine assay kits in IVD, identification of novel renal dysfunction biomarkers, and frequently changing regulatory policies are expected to restrain the growth of this market to a certain extent.

The creatinine assay kits market is highly fragmented with the presence of several small and big players. Prominent players in this market include Thermo Fisher Scientific (US), Merck (Germany), Abbott Laboratories (US), Abcam (UK), Quidel (US), Enzo Life Sciences (US), Cayman Chemical (US), Cell Biolabs (US), Genway Biotech (US), BioAssay Systems (US), Wako Pure Chemical Industries (Japan), Tulip Diagnostics (India), BioVision (US), and Arbor Assays (US).

To speak to our analyst for a discussion on the above findings, click Speak to Analyst